Skip to content

Study · Randomized controlled trial · n = 466 · 2022

4 results

A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg.

Seino Y, Miyoshi H, Bosch Traberg H, Divyalasya TVS, Nishijima K, Terauchi Y

Journal of diabetes investigation8 Apr 2022Cited by 2 (Europe PMC)

PMID35285173 (opens in a new tab)PMCIDPMC9340870 (opens in a new tab)DOI10.1111/jdi.13789 (opens in a new tab)PepBankPUB-35285173
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with type 2 diabetes and an inadequate response to liraglutide 0.9 mg, escalation to 1.8 mg lowered HbA1c more than staying on 0.9 mg at 26 weeks.

    In plain wordsIn Japanese adults with type 2 diabetes, liraglutide 1.8 mg lowered HbA1c more than liraglutide 0.9 mg.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change from baseline at week 26
    Study

    n = 466

    Comparator
    Liraglutide 0.9 mg
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg once daily · 26 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference
    −0.4%
    1.8 mg vs 0.9 mg

    Source sentences

    Summary
    After 26 weeks of treatment, liraglutide 1.8 mg was more effective compared with 0.9 mg in lowering HbA1c levels, with an estimated treatment difference of -0.40% (95% confidence interval [CI] -0.55, -0.24; P < 0.0001).
    1 context sentence
    Summary · context
    This 26-week randomized trial (NCT02505334) enrolled Japanese adults with type 2 diabetes across 47 sites in Japan.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with type 2 diabetes, liraglutide 1.8 mg gave greater odds of reaching HbA1c below 7.0% than liraglutide 0.9 mg.

    In plain wordsIn Japanese adults with type 2 diabetes, more people reached HbA1c below 7.0% on liraglutide 1.8 mg than on 0.9 mg.

    Peptide
    Liraglutide
    Outcome
    IncreaseProportion reaching HbA1c below 7.0%
    Study

    n = 466

    Comparator
    Liraglutide 0.9 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg once daily · 26 weeksAs given in this study (human).

    Measurements

    Estimated odds ratio
    3.87
    HbA1c <7.0%, 1.8 mg vs 0.9 mg

    Source sentences

    Summary
    Liraglutide 1.8 mg was associated with significantly greater odds of participants reaching HbA1c <7.0% (estimated odds ratio [EOR] 3.87; 95% CI 2.12, 7.08; P < 0.0001) and ≤6.5% (EOR 3.78; 95% CI 1.36, 10.54; P = 0.0109) compared with 0.9 mg.
    1 context sentence
    Summary · context
    This 26-week randomized trial (NCT02505334) enrolled Japanese adults with type 2 diabetes across 47 sites in Japan.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with type 2 diabetes, liraglutide 1.8 mg gave greater odds of reaching HbA1c of 6.5% or lower than liraglutide 0.9 mg.

    In plain wordsIn Japanese adults with type 2 diabetes, more people reached HbA1c of 6.5% or lower on liraglutide 1.8 mg than on 0.9 mg.

    Peptide
    Liraglutide
    Outcome
    IncreaseProportion reaching HbA1c 6.5% or lower
    Study

    n = 466

    Comparator
    Liraglutide 0.9 mg
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg once daily · 26 weeksAs given in this study (human).

    Measurements

    Estimated odds ratio
    3.78
    HbA1c <=6.5%, 1.8 mg vs 0.9 mg

    Source sentences

    Summary
    Liraglutide 1.8 mg was associated with significantly greater odds of participants reaching HbA1c <7.0% (estimated odds ratio [EOR] 3.87; 95% CI 2.12, 7.08; P < 0.0001) and ≤6.5% (EOR 3.78; 95% CI 1.36, 10.54; P = 0.0109) compared with 0.9 mg.
    1 context sentence
    Summary · context
    This 26-week randomized trial (NCT02505334) enrolled Japanese adults with type 2 diabetes across 47 sites in Japan.
  4. 04HumanRandomized controlled trialSafety outcome

    In Japanese adults with type 2 diabetes, both liraglutide 0.9 mg and 1.8 mg were reported as well tolerated.

    In plain wordsIn Japanese adults with type 2 diabetes, both liraglutide doses were reported as well tolerated.

    Peptide
    Liraglutide
    Outcome
    No significant changeTolerability of both doses
    Study

    n = 466

    Comparator
    Liraglutide 0.9 mg
    Outcome group
    Adverse events · Whole body
    Studied dose
    0.9 mg and 1.8 mg once daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Both doses were well tolerated.
    1 context sentence
    Summary · context
    This 26-week randomized trial (NCT02505334) enrolled Japanese adults with type 2 diabetes across 47 sites in Japan.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.